Capture Of Bispecific Antibodies And Removal Of Product-Related Impurities
The biotherapeutics pipeline is becoming increasingly diverse as antibody variants move through preclinical stages to commercial manufacturing. Many of these variants, especially asymmetric bispecific antibodies, are prone to aggregation or to forming product-related impurities such as homodimers and half antibodies during cell culture. The similarities between these impurities present extra challenges for downstream processes. One potential solution is to initiate polishing at the capture step using differences in avidity. Explore the application of a resin with novel selectivity to purify challenging entities.
VIEW THE APPLICATION NOTE! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.
Subscribe to Drug Discovery Online X
Subscribe to Drug Discovery Online